SAN FRANCISCO — September 8, 2026

Structure Therapeutics reported positive clinical data across its two lead oral small-molecule programs for chronic weight management, highlighting continued development of ACCG-2671, an investigational dual amylin and calcitonin receptor agonist, and aleniglipron, an oral GLP-1 receptor agonist. The company’s latest update centers on the advancement of oral small-molecule approaches to obesity treatment, with ACCG-2671 entering the multiple ascending dose portion of its Phase 1/2a program and aleniglipron continuing to demonstrate sustained weight reduction in the ACCESS open-label extension. Structure Therapeutics is developing these programs with the goal of providing convenient, scalable oral alternatives to injectable metabolic therapies and expanding treatment options for people living with obesity and related metabolic diseases.

ACCG-2671 Shows Early Clinical Activity

ACCG-2671 demonstrated an approximately six-day half-life and early evidence of pharmacodynamic activity following single-dose administration, supporting continued evaluation of the investigational oral amylin program. In the Phase 1/2a single ascending dose study involving 31 healthy adults without obesity, the candidate showed rapid absorption and dose-proportional exposure, while no serious adverse events, drug-related treatment discontinuations or drug-induced liver injury events were reported. Exploratory findings included a 3.3% mean body weight reduction at Day 24 following a single 10 mg dose, while CTX-1, a biomarker associated with bone resorption, decreased by approximately 60% across active dose groups at Day 2. Structure has now begun dosing participants in the 84-day multiple ascending dose study, which will evaluate different doses, titration strategies and daily or weekly administration schedules in people living with obesity. The study will also examine ACCG-2671 in combination with an injectable GLP-1 receptor agonist, with topline results expected in the first half of 2027.

Aleniglipron Delivers Sustained Weight Reduction

Structure Therapeutics also reported 72-week data for aleniglipron from the ACCESS open-label extension, providing additional evidence on long-term oral GLP-1 treatment and tolerability. Participants who continued from the 45 mg, 90 mg and 120 mg groups and were titrated toward 180 mg achieved mean weight reductions of 11.6%, 14.4% and 16.2%, respectively, at Week 72, with no evidence of a weight-loss plateau in the two highest dose groups. More than one-third of participants in the highest dose cohorts achieved more than 20% body weight reduction. The company also reported that fewer than 5% of participants discontinued treatment because of adverse events during the open-label extension. A lower 2.5 mg starting dose followed by gradual four-week titration improved gastrointestinal tolerability compared with the 5 mg starting dose used previously. These findings support Structure’s ongoing evaluation of aleniglipron as a once-daily oral GLP-1 therapy for chronic weight management.

Advertisement

cGxPJobs Banner

Structure Builds Two Oral Metabolic Programs

The latest clinical update strengthens Structure Therapeutics’ broader strategy of developing oral small-molecule medicines for obesity, with two complementary mechanisms progressing through clinical development. ACCG-2671 is being evaluated as a potential oral amylin-based therapy that could potentially be used alone or alongside GLP-1 medicines, while aleniglipron is advancing as a once-daily oral GLP-1 receptor agonist. Aleniglipron is currently being evaluated in the Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 trials, which are designed to assess long-term efficacy and safety in adults with obesity or overweight, including people with type 2 diabetes. Topline Phase 3 results are expected in the second half of 2028. Additional 2026 data from body composition, type 2 diabetes and treatment-switching studies could further define the clinical profile of aleniglipron. For Structure Therapeutics, the simultaneous advancement of oral amylin and oral GLP-1 programs represents the company’s central strategy to develop scalable, potentially more convenient therapies for the growing global obesity treatment market.

Source: Structure Therapeutics press release